Teva (NYSE:TEVA) said last week that it launched a generic version of Pfizer‘s (NYSE:PFE) Flector diclofenac epolamine patch.
Using a nonsteroidal anti-inflammatory drug, the topical patch is designed to treat acute pain due to minor strains, sprains and contusions.
Pfizer’s Flector patch garnered annual sales of $123 million in the U.S. as of Dec. 2018, according to IQVIA.
“The launch of our authorized generic of Flector Patch in the U.S. is an important addition to Teva’s portfolio of over 40 generic pain management medicines,” Brendan O’Grady, EVP & head of Teva’s North America commercial division, said in prepared remarks.
Last month, Teva reported that it expects its generic EpiPen auto-injector to hold 25% of the U.S. market by the end of 2019.
Mylan‘s (NSDQ:MYL) brand-name emergency allergy device has dominated the U.S. market for years. After Mylan faced widespread criticism for the price of its EpiPen product, the company launched its own generic for roughly $300.
Teva launched its generic EpiPen auto-injector in November, but priced the product in line with Mylan’s EpiPen generic.
